Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters

Journal of Infectious Diseases

Volumn 194, Issue 9, 2006, Pages 1300-1308

  Morrey, John D ^a   Siddharthan, Venkatraman ^a   Olsen, Aaron L ^a   Roper, Grant Y ^a   Wang, Hong ^a   Baldwin, Thomas J ^a   Koenig, Scott ^b   Johnson, Syd ^b   Nordstrom, Jeffrey L ^b   Diamond, Michael S ^c  

^a UTAH STATE UNIVERSITY   (United States)

^b Analytical Sciences   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HE16; PALIVIZUMAB; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; FEMALE; HAMSTER; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS INFECTION; SURVIVAL RATE; VIRUS ENCEPHALITIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; WEST NILE FEVER; WEST NILE VIRUS;

EID: 33750284191     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508293     Document Type: Article

References (39)

1. Haahr S. The influence of Poly I:C on the course of infection in mice inoculated with West Nile virus. Arch Gesamte Virusforsch 1971; 35:1-9.
2. Roehrig JT, Staudinger LA, Hunt AR, Mathews JH, Blair CD. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann NY Acad Sci 2001; 951:286-97.
3. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188:5-12.
4. Morrey JD, Day CW, Julander JG, et al. Modeling hamsters for evaluating West Nile virus therapies. Antiviral Res 2004; 63:41-50.
5. Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005; 11:1174-9.
6. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 2003; 77:12941-9.
7. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004; 10:1366-73.
8. Diamond MS, Klein RS. West Nile virus: crossing the blood-brain barrier. Nat Med 2004; 10:1294-5.
9. Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005; 11:522-30.
10. Diamond MS, Sitati EM, Friend LD, Higgs S, Shrestha B, Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 2003; 198:1853-62.
11. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 1974; 130:634-11.
12. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77:2578-86.
13. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 2001; 7:714-21.
14. Gould LH, Sui J, Foellmer H, et al. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 2005; 79:14606-13.
15. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002; 55:107-16.
16. Sidwell RW, Huffman JH. Use of disposable micro tissue culture plates for antiviral and interferon induction studies. Appl Microbiol 1971; 22:797-801.
17. Shi PY, Kauffman EB, Ren P, et al. High-throughput detection of West Nile virus RNA. J Clin Microbiol 2001; 39:1264-71.
18. Julander JG, Winger QA, Olsen AL, Day CW, Sidwell RW, Morrey JD. Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival. Antiviral Res 2005; 65:79-85.
19. Julander JG, Winger QA, Rickords LF, et al. West Nile virus infection of the placenta. Virology 2006; 347:175-82.
20. Occhiogrosso G, Edgar MA, Sandberg DI, Souweidane MM. Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery 2003; 52:388-93; discussion 393-4.
21. Sandberg DI, Edgar MA, Souweidane MM. Convection-enhanced delivery into the rat brainstem. J Neurosurg 2002; 96:885-91.
22. Morin LPW, Ruth I. A stereotaxic atlas of the golden hamster brain. 1st ed. San Diego: Academic Press, 2001.
23. Frankmann SP. A technique for repeated sampling of CSF from the anesthetized rat. Physiol Behav 1986; 37:489-93.
24. Kiyosawa K, Mokuno K, Murakami N, et al. Cerebrospinal fluid 28-kDa calbindin-D as a possible marker for Purkinje cell damage. J Neurol Sci 1993; 118:29-33.
25. Bakalian A, Delhaye-Bouchaud N, Mariani J. Quantitative analysis of the Purkinje cell and the granule cell populations in the cerebellum of nude mice. J Neurogenet 1995; 9:207-18.
26. Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother 2004; 15:101-9.
27. Klein RS, Lin E, Zhang B, et al. Neuronal CXCL10 directs CD8+ T- cell recruitment and control of West Nile virus encephalitis. J Virol 2005; 79:11457-66.
28. Gea-Banacloche J, Johnson RT, Bagic A, Butman JA, Murray PR, Agrawal AG. West Nile virus: pathogenesis and therapeutic options. Ann Intern Med 2004; 140:545-53.
29. Briese T, Glass WG, Lipkin WI. Detection of West Nile virus sequences in cerebrospinal fluid. Lancet 2000; 355:1614-5.
30. Huang C, Slater B, Rudd R, et al. First isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis 2002; 8:1367-71.
31. Solomon T, Ooi MH, Beasley DW, Mallewa M. West Nile encephalitis. BMJ 2003; 326:865-9.
32. Satoh J, Yukitake M, Kurohara K, Takashima H, Kuroda Y. Detection of the 14-3-3 protein in the cerebrospinal fluid of Japanese multiple sclerosis patients presenting with severe myelitis. J Neurol Sci 2003; 212:11-20.
33. Muller WE, Laplanche JL, Ushijima H, Schroder HC. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech Ageing Dev 2000; 116:193-218.
34. Ratterree MS, Gutierrez RA, Travassos da Rosa AP, et al. Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. J Infect Dis 2004; 189:669-76.
35. Arroyo J, Miller C, Catalan J, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78:12497-507.
36. Austgen LE, Bowen RA, Bunning ML, Davis BS, Mitchell CJ, Chang GJ. Experimental infection of cats and dogs with West Nile virus. Emerg Infect Dis 2004; 10:82-6.
37. Bunning ML, Bowen RA, Cropp B, et al. Experimental infection of horses with West Nile virus and their potential to infect mosquitoes and serve as amplifying hosts. Ann NY Acad Sci 2001; 951:338-9.
38. Siger L, Bowen RA, Karaca K, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 2004; 65:1459-62.
39. Minke JM, Siger L, Karaca K, et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 2004:221-30.